ZFAND5 and stroke disorder: These data provide experimental evidence that stroke causes muscle atrophy, in part, through PARP‐1‐regulated ZNF216 protein and inhibition of PARP‐1 activity in the post‐stroke muscle may have a beneficial effect in reversing the stroke‐induced muscle loss through ZNF216 inhibition.